Quarterly report pursuant to Section 13 or 15(d)

Schedule of Restricted Stock Award Activity (Details)

v3.22.2.2
Schedule of Restricted Stock Award Activity (Details) - Restricted Stock Units (RSUs) [Member]
6 Months Ended
Jun. 30, 2022
$ / shares
shares
2014 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Stock Options Outstanding, Beginning Balance | shares 1,666,666
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares $ 2.36
Number of Stock Options, Granted | shares [1]
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Stock Options, Vested | shares (541,666)
Weighted Average Grant Date Fair Value, Vested | $ / shares $ 1.20
Number of Stock Options, Forfeited | shares (150,000)
Weighted Average Grant Date Fair Value, Forfeited | $ / shares $ 2.04
Number of Stock Options Outstanding, Ending Balance | shares 975,000 [1]
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares $ 3.05 [1]
2018 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Stock Options Outstanding, Beginning Balance | shares 1,940,740
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares $ 12.76
Number of Stock Options, Granted | shares 320,000 [2]
Weighted Average Grant Date Fair Value, Granted | $ / shares $ 4.53
Number of Stock Options, Vested | shares
Weighted Average Grant Date Fair Value, Vested | $ / shares
Number of Stock Options, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Stock Options Outstanding, Ending Balance | shares 2,260,740 [2]
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares $ 11.59 [2]
[1] The unvested restricted stock awards presented in the table above, are inclusive of 100,000 restricted stock awards granted outside the PAVmed Inc. 2014 Equity Plan. as of June 30, 2022 and December 31, 2021.
[2] The unvested restricted stock awards presented in the table above, are inclusive of 50,000 restricted stock awards granted outside the Lucid Diagnostics Inc. 2018 Equity Plan. as of June 30, 2022 and December 31, 2021.